Frazier Life Sciences Management, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001892134

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q4 2023 · 49 positions · Total reported value $1.87B · Top-10 concentration 59.4% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 22.7% · 6 new · 1 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +20.6% · vs SPY +5.8% · Prev Value $3.89B — last quarter positions weighted by this quarter price moves · ranking

In its Q4 2023 13F filing, Frazier Life Sciences Management, L.P. disclosed 49 equity positions with a combined reported value of $1.87B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 59.4% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2023 were MIRM ($191.74M), HLVX ($156.99M), NAMS ($135.51M). By sector, the heaviest allocations are Health Care 71.1%, Materials 0.1%. Versus the prior quarter, allocation shifted toward Other (+2.1pp) and away from Health Care (-2.1pp).

Versus the prior quarter, Frazier Life Sciences Management, L.P. opened 6 new positions, trimmed 1 and fully exited 3, a turnover rate of 22.7% of positions. The portfolio's overlap with the prior quarter was 79% of names.

The largest new positions opened in Q4 2023 were ETNB ($22.34M), MDGL ($16.06M), DYN ($15.76M).

Of the 3 positions fully exited versus the prior quarter, the largest were ELVN ($14.35M), REPL ($6.62M), PRTA ($6.17M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2023)

  • ETNB 89BIO INC · $22.34M
  • MDGL MADRIGAL PHARMACEUTICALS INC · $16.06M
  • DYN DYNE THERAPEUTICS INC · $15.76M
  • GPCR STRUCTURE THERAPEUTICS INC · $12.93M
  • MRTX MIRATI THERAPEUTICS INC · $4.70M

Fully Exited (vs previous quarter)

  • ELVN ENLIVEN THERAPEUTICS INC · prev qtr: $14.35M
  • REPL REPLIMUNE GROUP INC · prev qtr: $6.62M
  • PRTA PROTHENA CORP PLC · prev qtr: $6.17M
  • STRO SUTRO BIOPHARMA INC · prev qtr: $2.71M
  • SNDX SYNDAX PHARMACEUTICALS INC · prev qtr: $1.57M
  • ADCT ADC THERAPEUTICS SA · prev qtr: $1.48M
  • PASG Passage Bio Inc · prev qtr: $1.16M

Insider Transactions (Form 4)

Latest Frazier Life Sciences Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Frazier Life Sciences Management, L.P. is an SEC-registered 13F filer. As of Q2 2026 it reported 41 US equity positions with a combined value of $4.59B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 41 positions · $4.59B reported value (Q2 2026)
  • Top 10 holdings = 73.6% of reported value
  • Largest position: MIRM (MIRUM PHARMACEUTICALS INC) at 19.6%
  • Average position size: $112.00M

Sector Tilt

  • Health Care 99.8%
  • Materials 0.2%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 6 new, 8 added, 1 reduced, 3 exited
  • 26 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 71.1%
Materials 0.1%
Other 28.8%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 6.50M $191.74M 10.25%
10.25%
Hold
2 9.78M $156.99M 8.39%
8.39%
Hold
3 12.13M $135.51M 7.25%
7.25%
Hold
4 988.46K $122.63M 6.56%
6.56%
Hold
5 2.73M $110.05M 5.88%
5.88%
Hold
6 2.37M $109.01M 5.83%
5.83%
Hold
7 10.11M $92.30M 4.93%
4.93%
Hold
8 1.16M $73.12M 3.91%
3.91%
Hold
9 3.01M $59.93M 3.20%
3.20%
Hold
10 3.13M $59.68M 3.19%
3.19%
Add
11 885.16K $52.99M 2.83%
2.83%
Add
12 1.52M $45.64M 2.44%
2.44%
Add
13 785.00K $45.34M 2.42%
2.42%
Add
14 3.62M $44.37M 2.37%
2.37%
Add
15 1.79M $36.20M 1.94%
1.94%
Hold
16 2.67M $29.18M 1.56%
1.56%
Add
17 997.46K $28.61M 1.53%
1.53%
Hold
18 1.39M $28.46M 1.52%
1.52%
Hold
19 8.76M $28.31M 1.51%
1.51%
Add
20 1.20M $27.27M 1.46%
1.46%
Hold
21 3.75M $24.13M 1.29%
1.29%
Hold
22 2.40M $23.10M 1.24%
1.24%
Add
23 730.92K $22.89M 1.22%
1.22%
Add
24 2.00M $22.34M 1.19%
1.19%
New
25 746.48K $20.53M 1.10%
1.10%
Hold
26 2.14M $19.71M 1.05%
1.05%
Hold
27 899.70K $19.27M 1.03%
1.03%
Hold
28 4.00M $18.80M 1.00%
1.00%
Hold
29 464.94K $18.71M 1.00%
1.00%
Hold
30 393.00K $16.66M 0.89%
0.89%
Hold
31 1.02M $16.48M 0.88%
0.88%
Add
32 69.41K $16.06M 0.86%
0.86%
New
33 1.18M $15.76M 0.84%
0.84%
New
34 881.17K $15.31M 0.82%
0.82%
Hold
35 1.03M $14.22M 0.76%
0.76%
Hold
36 397.48K $14.14M 0.76%
0.76%
Reduce
37 317.19K $12.93M 0.69%
0.69%
New
38 285.33K $11.74M 0.63%
0.63%
Hold
39 2.00M $11.73M 0.63%
0.63%
Add
40 523.17K $11.65M 0.62%
0.62%
Add
41 400.00K $11.18M 0.60%
0.60%
Hold
42 7.38M $9.89M 0.53%
0.53%
Add
43 2.12M $8.58M 0.46%
0.46%
Reduce
44 203.68K $6.21M 0.33%
0.33%
Hold
45 80.00K $4.70M 0.25%
0.25%
New
46 1.71M $2.36M 0.13%
0.13%
Hold
47 1.03M $2.10M 0.11%
0.11%
Reduce
48 500.33K $1.57M 0.08%
0.08%
Hold
49 264.38K $277.60K 0.01%
0.01%
Hold

FAQ

What did Frazier Life Sciences Management, L.P. buy in 2023-Q4?

In its 2023-Q4 13F filing, Frazier Life Sciences Management, L.P. reported 49 equity positions worth $1.87B in aggregate; its largest disclosed positions were MIRM ($191.74M), HLVX ($156.99M), NAMS ($135.51M).

How large is Frazier Life Sciences Management, L.P.'s portfolio?

Frazier Life Sciences Management, L.P. reported $1.87B of long equity holdings across 49 positions as of 2023-Q4. Top-10 holdings account for 59.4% of reported value.

What is Frazier Life Sciences Management, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/frazier-life-sciences-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →